Monoclonal antibodies (MAbs) are inherently sensitive to handle. In an effort to improve the specificity of oncology treatment, many pharma and biotech worked on combining these MAbs with cytotoxins to kill cancer cells. While it is challenging to synthesis these Antibody-drug conjugate (ADC) in lab, it is even harder to mass produce these macromolecules to run it through clinical trials phase and beyond. As a result, many researchers struggle to understand the best way in maintaining ADC functionality while reaching the required volume for sufficient profitability.
In 2013, Seattle Genetics made a breakthrough to obtained US FDA approval for its Adcetris®, an ADC for treating Hodgkins lymphoma, a common cancer in the states. With its approval, this 5.93 billion USD capital biotech gained a high volume of publicity and wealth for this success.
We are sure that Adcetris® will not be the last ADC to ever be developed by global biotech and pharma so here at BioPharma Asia 2016, we thought you’d like to hear from the most qualified person to advise on the best strategy to adopt in order to fast track the commercialisation of these sensitive macromolecules. If you are working in the antibody sphere, you will need to hear from Peter Senter, Vice President of Chemistry at Seattle Genetics to learn how he and his team has successfully brought these sensitive antibody-based therapy from early development stage to clinical trials and beyond. We are confident that his sharing will allow you to re-strategise and speed up the commercialisation of your ADC pipelines.
Book your place now and join us in Singapore this March.
About BioPharma Asia Convention 2016
The 9th BioPharma Asia Convention is the largest regional B2B event in the industry, bringing more than 1500 attendees annually. The 2016 program will be bigger than ever before, offering you more tracks, more content and more value. Our 7 premium conference tracks will explore innovation in clinical trials, manufacturing, supply chain, market access, partnering, pricing, vaccines & infectious diseases, antibodies, orphan drugs, biosimilars, stem cells and more.
About Peter Senter, Vice President, Chemistry, Seattle Genetics
Peter Senter joined Seattle Genetics in August 1998 and has served as Vice President, Chemistry since September 2002. In February 2009, Dr. Senter was recognized as the company’s first Distinguished Fellow. He leads Seattle Genetics’ chemistry department, which carries out research in antibody-drug conjugate technologies, including the development of potent drug payloads, novel linker systems, conjugation methodology and mechanism of action studies. Prior to joining the company, Dr. Senter was with Cytokine Networks, Inc., the Bristol-Myers Squibb Pharmaceutical Research Institute and the Dana-Farber Cancer Institute, Harvard Medical School. Dr. Senter received an A.B. in Biochemistry from the University of California, Berkeley, a Ph.D. in Chemistry from the University of Illinois, and did postdoctoral research at the Max Planck Institute of Experimental Medicine in Göttingen, Germany. He is the Senior Editor of Molecular Cancer Therapeutics (published by the American Association of Cancer Research) and serves as an Affiliate Professor of Bioengineering at the University of Washington. His research interests include targeted drug delivery, protein chemistry and biochemistry, and anti-cancer drug design. Dr. Senter has authored more than 150 scientific publications and holds more than 40 patents. – See more at: http://www.terrapinn.com/exhibition/bio-asia/speaker-peter-SENTER.stm#sthash.DXRGF0c3.dpuf